10-Q: Glaukos Narrows Q2 Loss on Strong iDose TR Sales

Glaukos Corporation reported a significant reduction in net loss for the second quarter and first half of 2025, driven by robust sales growth in glaucoma products, particularly iDose TR, and improved gross margins.

Summary

• Net sales for the three months ended June 30, 2025, increased by 30% to $124.1 million, up from $95.7 million in the prior year period.
• Net sales for the six months ended June 30, 2025, increased by 27% to $230.8 million, up from $181.3 million in the prior year period.
• The net loss for the second quarter of 2025 significantly decreased by 61% to $19.7 million, compared to $50.5 million in the same period last year.
• The net loss for the first half of 2025 decreased by 59% to $37.8 million, compared to $91.4 million in the first half of last year.
• Gross margin improved to 78% for both the three and six months ended June 30, 2025, up from 76% in the corresponding periods of 2024.
• Operating expenses increased by 16% for the quarter and 7% for the six months, primarily due to higher selling, general and administrative costs related to compensation, stock-based compensation, and commercial infrastructure growth.
• Cash and cash equivalents decreased to $100.8 million as of June 30, 2025, from $169.6 million at December 31, 2024, with total cash, cash equivalents, short-term investments, and restricted cash at $278.6 million.
• The company acquired Mobius Therapeutics, LLC on May 16, 2025, for $12.4 million net of cash acquired, plus potential contingent consideration of up to $80.0 million based on net sales milestones.
• Glaukos also purchased an adjacent 40,000 square foot building in Aliso Viejo, California, for $16.6 million on April 4, 2025, for future expansion opportunities.
• Received European Union (EU) Medical Device Regulation (MDR) certification for iStent family products in June 2025, with commercial launch expected in key EU markets in the second half of 2025.

Sentiment

Score: 7

Explanation: The company demonstrated strong revenue growth and a significant reduction in net losses, indicating positive operational momentum and successful product commercialization efforts. Strategic acquisitions and EU market certifications further bolster future prospects. However, continued unprofitability, a decrease in cash balance, and ongoing market challenges like reimbursement complexities and increased competition temper the overall positive sentiment.

Positives

• Net sales increased significantly by 30% for the quarter and 27% for the six months, demonstrating strong top-line growth.
• Net loss decreased substantially by 61% for the quarter and 59% for the six months, indicating improved operational efficiency and reduced cash burn.
• Gross margin improved to 78%, reflecting better cost management or product mix.
• U.S. Glaucoma sales increased by 45% for the quarter and 43% for the six months, primarily driven by higher iDose TR volumes.
• International Glaucoma sales grew by 20% for the quarter and 17% for the six months, with broad-based volume growth in key markets like Japan, France, the United Kingdom, and Germany, aided by favorable foreign exchange rates.
• Acquisition of Mobius Therapeutics, LLC expands the company's portfolio with Mitosol, an FDA-approved ophthalmic formulation for glaucoma procedures.
• Purchase of the Aliso Building provides future expansion opportunities and potential reduction in future capital expenditures.
• Receipt of EU MDR and UKMDR certification for iStent family products opens up significant commercial launch opportunities in key European markets in the second half of 2025.
• iDose TR received a unique, permanent J-code (J7355) effective July 1, 2024, streamlining billing and reimbursement, and temporary CPT codes were assigned retroactively to January 1, 2024.

Negatives

• The company continues to incur net losses, with an accumulated deficit of $783.2 million as of June 30, 2025.
• Cash and cash equivalents decreased by $68.8 million from December 31, 2024, to June 30, 2025.
• U.S. Glaucoma sales of the iStent family of products were negatively impacted by lower volumes due to MIGS restrictions associated with final Local Coverage Determinations (LCDs) issued by five Medicare Administrative Contractors (MACs).
• Royalty income from the settlement agreement with Ivantis, Inc. (Hydrus Microstent) contractually expired on April 26, 2025, removing a source of revenue.
• International corneal health sales decreased by $0.4 million for the quarter and $0.5 million for the six months.
• Anticipated potential disruption within the U.S. Corneal Health franchise as the market transitions from Photrexa to Epioxa following its potential approval.
• Increased competition from other products entering the market and similar products being developed by third parties.
• Orphan drug exclusivity for Photrexa expired in 2023, enabling third parties to develop potentially competitive products.

Risks

• Failure to achieve commercial success of iDose TR due to factors like physician adoption, consistent reimbursement, manufacturing capacity, marketing compliance, patient outcomes, pricing, efficacy duration, and payor coverage.
• Adverse effects from unfavorable global and regional macroeconomic conditions, including inflation, volatility in financial markets, higher interest rates, labor shortages, increased energy costs, and currency fluctuations.
• Risks associated with public health crises, such as impacts or delays to product development, staffing shortages, manufacturing disruptions, and restrictions on personnel access to customers.
• Material disruption in the supply and/or manufacture of principal revenue-producing products (iStent family, Photrexa, iDose TR) due to reliance on sole manufacturing locations and limited third-party suppliers.
• Inability to reach sustained profitability and generate positive cash flow in the future, despite past profitable periods.
• Failure to generate sufficient sales of commercialized products or to develop and commercialize additional products, which are expensive and time-consuming with uncertain success.
• Risks associated with international operations, including differing regulatory processes, intellectual property protection, pricing pressure, competitive dynamics, political/economic instability, tariffs, and foreign currency fluctuations.
• Damage to reputation and negative impact on sales and operating earnings if product quality or delivery does not meet customer expectations, leading to potential shipment holds, recalls, or product liability suits.
• Ophthalmic surgeons may not use products if they do not believe they are safe, efficient, effective, or preferable, or misuse could lead to inferior clinical outcomes.
• Failure to manage anticipated growth effectively, potentially straining manufacturing capacity, increasing competition, and challenging personnel management.
• Inability to retain or recruit qualified personnel, including senior management and sales representatives.
• Acquisitions, collaborations, in-licensing agreements, joint ventures, alliances, or partnerships with third parties could fail or result in litigation.
• Cybersecurity incidents, service interruptions, or data corruption could materially disrupt operations, affect internal controls, and lead to decreased sales or loss of intellectual property.
• Failure to comply with data privacy and security laws (e.g., HIPAA, GDPR, CCPA, AI regulations) could result in significant liability, fines, and penalties.
• Net operating loss tax carryforwards may not be fully available or may be subject to limitations, potentially increasing future tax liabilities.
• Future indebtedness could limit cash flow and adversely affect financial condition and operating results.
• Capped call transactions may affect the value of common stock and subject the company to counterparty risk.
• Healthcare legislative reform measures and changes in U.S. and international trade policies could adversely affect business and results of operations, including pricing and reimbursement.
• Costly compliance with extensive U.S. and international regulations (FDA, state, foreign, EU MDR, UKMDR), with potential for enforcement actions for non-compliance.
• Inadequate or inconsistent reimbursement for products from third-party payors could adversely impact business, including changes in coverage policies or payment rates.

Future Outlook

The company anticipates increased utilization of iDose TR as reimbursement becomes more timely and consistent across all Medicare Administrative Contractors (MACs). It expects some supply challenges and higher costs of certain components and raw materials to continue throughout 2025. The Prescription Drug User Fee Act (PDUFA) date for Epioxa is October 20, 2025, and its potential approval is expected to cause some market disruption as patients transition from Photrexa. A PDUFA date in January 2026 is set for the supplemental new drug application (NDA) for iDose TR re-administration, though approval is not assured. The company expects capital expenditures to be higher in 2025 than in 2024 due to facility upgrades and R&D equipment investments, with construction of a new R&D and manufacturing facility in Huntsville, Alabama, expected to begin in 2026. Expenses are projected to continue increasing due to investments in R&D, clinical studies, manufacturing, sales and marketing, and infrastructure.

Management Comments

• We incurred net losses for the three and six months ended June 30, 2025 of $19.7 million and $37.8 million, respectively, and incurred net losses of $50.5 million and $91.4 million for the three and six months ended June 30, 2024, respectively.
• As of June 30, 2025, we had an accumulated deficit of $783.2 million.
• We expect some supply challenges and higher costs of certain components and raw materials to continue throughout 2025.
• We expect to commence commercial launch activities in our key EU markets in the second half of 2025.
• As reimbursement for the iDose TR procedure continues to become a more timely and consistent process across all MACs, we anticipate utilization of iDose TR by our customers will increase accordingly.
• CMS physician fee payment rate decreases, along with the finalization in late 2024 of recent LCDs issued by five of the seven MACs, have disrupted traditional customer ordering patterns and may have resulted in certain of our customers utilization of competitive products, which has reduced U.S. Glaucoma sales volumes of our iStent family of products used in conjunction with cataract surgery in each of the three and six months ended June 30, 2025 and June 30, 2024.
• Additionally, the royalty income we received pursuant to a settlement agreement entered into during 2021 with Ivantis, Inc. (acquired by Alcon in 2022) relating to sales of the Hydrus Microstent contractually expired on April 26, 2025.
• Because Epioxa is designed to preserve the corneal epithelium, streamline the procedure, improve patient comfort and shorten recovery time, we anticipate some potential disruption within our U.S. Corneal Health franchise as the market transitions from Photrexa to Epioxa following its potential approval.
• While we believe we have sufficient cash to fund our operations for at least the next 12 months from the date our condensed consolidated financial statements for the quarter ended June 30, 2025 are made publicly available, our ability to reach sustained profitability and generate positive cash flow in the future is highly uncertain.
• We expect levels of our capital expenditures to be higher in 2025 than in 2024 as we upgrade certain manufacturing facilities and continue investing in R&D equipment needed to advance our pipeline.

Industry Context

The company operates within the ophthalmic pharmaceutical and medical technology sector, which is subject to ongoing macroeconomic conditions including inflation, supply shortages, and foreign exchange rate fluctuations. The healthcare industry is also heavily influenced by legislative and regulatory reforms, such as changes in U.S. and international trade policies, Medicare payment rates set by CMS and MACs, and drug pricing regulations like the Medicaid Drug Rebate Program (MDRP) and the Inflation Reduction Act. The company faces increasing competition from both established players and new entrants, particularly as orphan drug exclusivity for its Photrexa therapy expired, and new products like iDose TR navigate complex reimbursement landscapes. The sector is characterized by high R&D investment and the need for continuous innovation to maintain competitive advantage.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct industry standard comparisons.
• The company notes that certain local coverage determinations (LCDs) by Medicare Administrative Contractors (MACs) have disrupted traditional customer ordering patterns for its iStent family of products, potentially leading to utilization of competitive products, indicating a challenging reimbursement environment for some of its offerings compared to market expectations or competitor performance.
• The expiration of royalty income from Ivantis, Inc. (acquired by Alcon) for the Hydrus Microstent highlights the competitive landscape in the MIGS market, where other products are available.
• The company acknowledges that it commercialized certain products for several years with few direct competitors, but now faces increased competition, suggesting a shift in market dynamics towards more competitive pressures.

Related Party Transactions

• A member of the Celanese board of directors also sits on the company's board of directors. The company has a sales agreement with Celanese Canada ULC for raw materials used in iDose TR, involving minimum compensation payments of $6.3 million over four years and potential additional royalties.

Stakeholder Impact

• Shareholders: Experienced a significant reduction in net loss per share, but the company remains unprofitable with an increasing accumulated deficit. Executive 10b5-1 trading plans were adopted.
• Employees: Benefit from increased compensation and stock-based compensation, but the company faces risks in retaining and recruiting qualified personnel.
• Customers: Benefit from new product offerings like iDose TR and potential future products like Epioxa, but may experience disruptions due to changing reimbursement policies and supply chain challenges affecting product availability.
• Suppliers: The company's reliance on a limited number of third-party suppliers poses a risk of disruption if these suppliers face issues.
• Creditors: The company's liquidity is deemed sufficient for the next 12 months, and convertible notes were fully exchanged/redeemed in 2024, reducing immediate debt obligations.

Next Steps

• Commence commercial launch activities for iStent family products in key EU markets in the second half of 2025.
• Anticipate increased utilization of iDose TR as reimbursement becomes more timely and consistent across all MACs.
• Await FDA approval decision for Epioxa by its PDUFA date of October 20, 2025.
• Await FDA approval decision for the supplemental new drug application (NDA) for re-administration of iDose TR by its PDUFA date in January 2026.
• Continue to upgrade certain manufacturing facilities and invest in R&D equipment in 2025.
• Begin construction of a new 200,000 square foot R&D and manufacturing facility in Huntsville, Alabama, in 2026.

Key Dates

Recommendation

While Glaukos demonstrated strong revenue growth and a significant reduction in net losses, indicating positive operational momentum and successful product commercialization, the company remains unprofitable with a growing accumulated deficit. The cash balance decreased, and ongoing challenges such as reimbursement complexities for iStent products and increased competition persist. Strategic acquisitions and EU market certifications are positive long-term drivers, but the path to sustained profitability and positive cash flow remains uncertain. A 'hold' recommendation is appropriate for existing investors to monitor the execution of strategic initiatives and the impact of new product launches on profitability, while new investors may consider waiting for clearer signs of sustained positive cash flow.

Keywords

Ophthalmic, Glaucoma, Corneal Health, Retinal Disease, MIGS, Micro-Invasive Glaucoma Surgery, iDose TR, iStent, Photrexa, Epioxa, Medical Device, Pharmaceutical, FDA Approval, SEC Filing, 10-Q, Financial Results, Healthcare, Biotechnology, Medical Technology, Reimbursement, Clinical Trials, R&D, Acquisition, Mobius Therapeutics, EU MDR, Supply Chain